Related Experiment Video
Updated: Jun 27, 2026
08:55
A Practical Guide for the Production and PET/CT Imaging of 68Ga-DOTATATE for Neuroendocrine Tumors in Daily Clinical Practice
Published on: April 17, 2019
99mTc-HYNIC octreotide in neuroblastoma
Juan P Gambini1, Juan J López Lerena, Adriana Quagliata
1Nuclear Medicine Center, Clinical Hospital, University of Uruguay, Av. Italia s/n, C.P. 11600, Montevideo, Uruguay.
Annals of Nuclear Medicine
|November 29, 2008
Summary
Technetium-99m (99mTc)-HYNIC-octreotide scintigraphy shows greater neuroblastoma lesion extension than iodine-131 (131I)-MIBG scans. This novel radiopharmaceutical offers a promising, cost-effective imaging agent for disease status assessment.
Area of Science:
- Nuclear medicine
- Oncology
- Radiopharmaceutical development
Background:
- Standard neuroblastoma staging involves imaging (CT, MRI, bone, MIBG scans), bone marrow tests, and urine catecholamines.
- Clinical experience with technetium-99m (99mTc)-somatostatin analog scintigraphy for neuroblastoma is lacking.
- Radiopharmaceuticals like 99mTc-HYNIC-octreotide are attractive due to potential cost-effectiveness, availability, and ease of preparation.
Observation:
- A single case study of an 8-year-old boy with stage-IV neuroblastoma post-chemotherapy was evaluated.
- Both iodine-131 (131I)-MIBG and 99mTc-HYNIC-octreotide scans were performed for tumor extension assessment.
- The 99mTc-HYNIC-octreotide scan revealed more extensive disease than the 131I-MIBG scan.
Findings:
- The 131I-MIBG scan showed mild uptake in the lung hila.
- The 99mTc-HYNIC-octreotide scan identified multiple bone and ganglionar uptakes in axial, appendicular, paravertebral, abdominal, mediastinal, and supraclavicular regions.
- 99mTc-HYNIC-octreotide demonstrated significantly greater lesion extension compared to 131I-MIBG.
Implications:
- 99mTc-HYNIC-octreotide shows potential as a superior radiopharmaceutical for evaluating neuroblastoma.
- This finding supports further investigation of 99mTc-HYNIC-octreotide in clinical trials for neuroblastoma.
- The development of cost-effective and readily available imaging agents is crucial for pediatric oncology.